Literature DB >> 8319163

Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine.

I J Roman1, M R Danzig.   

Abstract

Antihistamines are considered first-line therapy for the relief of symptoms from allergic rhinitis and chronic urticaria. The newer, second-generation, nonsedating antihistamines reduce the central nervous system and anticholinergic side effects commonly found with previous drugs. The availability of H1-receptor antagonists that produce therapeutic effects without causing unwanted CNS effects fulfills an important practical need, since these drugs are clearly preferable in patients who drive or operate heavy machinery, or who are involved in activities requiring full alertness. Physicians and patients alike are pleased with the efficacy and safety the second-generation antihistamines bring to the treatment of allergy symptoms. Loratadine is an especially effective second-generation H1-receptor antagonist and is comparable to many of the other second-generation antihistamines. Loratadine may be particularly advantageous because of its low dose and the convenience of once-daily dosing. A more subtle advantage, loratadine's antiallergic properties, may warrant its use for specific treatment situations as future research clarifies the nature of the inflammatory response and the mechanisms of action antiallergic antagonists have in this regard.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8319163     DOI: 10.1007/BF02802295

Source DB:  PubMed          Journal:  Clin Rev Allergy        ISSN: 0731-8235


  24 in total

1.  The effectiveness of the nonsedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold.

Authors:  R B Berkowitz; J T Connell; A J Dietz; S M Greenstein; D G Tinkelman
Journal:  Ann Allergy       Date:  1989-10

2.  Lack of subsensitivity to loratadine during long-term dosing during 12 weeks.

Authors:  J Bousquet; I Chanal; W Skassa-Brociek; C Lemonier; F B Michel
Journal:  J Allergy Clin Immunol       Date:  1990-08       Impact factor: 10.793

Review 3.  H1-receptor antagonists: clinical pharmacology and therapeutics.

Authors:  F E Simons
Journal:  J Allergy Clin Immunol       Date:  1989-12       Impact factor: 10.793

4.  Loratadine, a non-sedating H1-receptor antagonist (antihistamine)

Authors:  F E Simons
Journal:  Ann Allergy       Date:  1989-10

5.  Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis.

Authors:  J Del Carpio; L Kabbash; Y Turenne; M Prevost; J Hebert; P M Bedard; M Nedilski; A Gutkowski; J Schulz
Journal:  J Allergy Clin Immunol       Date:  1989-11       Impact factor: 10.793

6.  Skin test suppression by antihistamines and the development of subsensitivity.

Authors:  W F Long; R J Taylor; C J Wagner; D C Leavengood; H S Nelson
Journal:  J Allergy Clin Immunol       Date:  1985-07       Impact factor: 10.793

7.  A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis.

Authors:  L Frølund; B Etholm; K Irander; T A Johannessen; L Odkvist; B Ohlander; B Weeke
Journal:  Allergy       Date:  1990-05       Impact factor: 13.146

8.  Pharmacology of antihistamines.

Authors:  J K Woodward
Journal:  J Allergy Clin Immunol       Date:  1990-10       Impact factor: 10.793

Review 9.  Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  S P Clissold; E M Sorkin; K L Goa
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

10.  Antiallergic activity of loratadine, a non-sedating antihistamine.

Authors:  W Kreutner; R W Chapman; A Gulbenkian; M I Siegel
Journal:  Allergy       Date:  1987-01       Impact factor: 13.146

View more
  2 in total

1.  Effect of loratadine, an H1 antihistamine, on induced cough in non-asthmatic patients with chronic cough.

Authors:  S Tanaka; K Hirata; N Kurihara; J Yoshikawa; T Takeda
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

2.  Loratadine-associated cystoid macular edema: A case report.

Authors:  Yong Tang; Rui Dou; Yuyan Liu; Shiyong Xie; Quanhong Han
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.